Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A.
World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL.
Dig Liver Dis. 2014 Sep;46(9):833-7. doi: 10.1016/j.dld.2014.05.017. Epub 2014 Jun 19.
Treatment of hepatitis C-related kidney disease.
Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM.
Expert Opin Pharmacother. 2015;16(12):1815-27. doi: 10.1517/14656566.2015.1066333. Epub 2015 Jul 10.
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
How to optimize HCV therapy in genotype 1 patients: management of side-effects.
Chopra A, Klein PL, Drinnan T, Lee SS.
Liver Int. 2013 Feb;33 Suppl 1:30-4. doi: 10.1111/liv.12080.
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naive patients plus chronic hepatitis C.
Gimeno-Ballester V, Mar J, San Miguel R.
Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):285-94. doi: 10.1586/14737167.2015.1081061. Epub 2015 Aug 29.
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
Toro Montecinos M, Carrascosa Carrillo JM, Vilavella Rius M, Bielsa Marsol I, Plana Pla A, Morillas Cunill R, Planas Vilà R, Masnou Ridaura H, López Escartin D, Ferrándiz Foraster C.
Actas Dermosifiliogr. 2015 Apr;106(3):219-25. doi: 10.1016/j.ad.2014.07.004. Epub 2014 Oct 26.
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.
Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067.
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
Vince A, Duvnjak M, Kurelac I.
Acta Med Croatica. 2013 Oct;67(4):329-38.
